Managing Nano-Bio-Info-Cogno Innovations - World Technology ...

130
9. Nanotechnology for Biology and Medicine
appropriate to “improve” muscle function to improve athletic
competitiveness. In the same way that growth hormone has created moral
issues about short stature (Sandberg and Voss, 2002), will nanomedicine
create similar concerns about marginal intelligence, personality disorders,
and reproductive potential? Some way must be developed to obtain a societal
consensus to guide our science in these areas.
Although the concepts in this review are truly far ranging in scope and
timeline, they show the potential for nanomedicine. However, future
technology will have to pass economic tests as well as efficacy tests if it is to
be adopted. Therapeutics that do not save the health care system money will
find it difficult to gain wide acceptance, no matter how useful they may
seem. Therapies available only to the wealthy would undermine the social
fabric of human society. As with any therapeutic, the first rule of
nanomedicine will be “Primum non nocere” or first, do no harm. This is true
in the case of nanomedicine, whether the harm be medical or financial.
References
Anderson, S. A., R. K. Rader, W. F. Westlin, C. Null, D. Jackson, G. M. Lanza, S. A.
Wickline, and J. J. Kotyk. 2000. Magnetic resonance contrast enhancement of
neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magnetic Resonance
in Medicine 44: 433–439.
Banks, M. E. 2003. Disability in the family: A life span perspective. Cultural
Diversity and Ethnic Minority Psychology 9: 367–384.
Evans, G. R. 2000. Challenges to nerve regeneration. Seminars in Surgical Oncology
19: 312–318.
Derfus, A. M., W. C. W. Chan, and S. N. Bhatia. 2004. Probing the cytotoxicity of
semiconductor quantum dots. Nano Letters 4: 11–18.
Fritz, S. V., A. M. Singer, V. B. Revan, and J. R. Baker, Jr. 2002. Bioterrorism:
Relevance to allergy and immunology in clinical practice. The Journal of Allergy
and Clinical Immunology 109: 214–228.
Gill, D. R., L. A. Davies, I. A. Pringle, and S. C. Hyde. 2004. The development of
gene therapy for diseases of the lung. Cellular and Molecular Life Sciences 6:
355–368.
Hammel, J. 2003. Technology and the environment: Supportive resource or barrier
for people with developmental disabilities? Nursing Clinics of North America 38:
331–349.
Harisinghani, M. G., J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H.
van de Kaa, J. de la Rosette, and R. Weissleder. 2004. Noninvasive detection of
clinically occult lymph-node metastases in prostate cancer. New England Journal
of Medicine 348: 2491–2499.
Koifman, S., and R. J. Koifman. 2003. Environment and cancer in Brazil: An
overview from a public health perspective. Mutation Research 544: 305–311.
Kong, G., R. D. Braun, and M. W. Dewhirst. 2000. Hyperthermia enables tumorspecific
nanoparticle delivery: effect of particle size. Cancer Research 60: 4440–
4445.